Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC
- Sponsor
- Tang-Du Hospital
- Study ID
- NCT04338620
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Non-small-cell Lung Cancer (NSCLC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- camrelizumab、albumin-bound paclitaxel and platinum — DRUGExperimental Group:camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
- albumin-bound paclitaxel and platinum — DRUGControl group:albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
Study Details
Explorative study, which evaluates the effect of Camrelizumab combined with albumin-bound paclitaxel and platinum in neoadjuvant treatment of resectable non-small-cell lung carcinoma.
Key Dates
- Start date
- Apr 7, 2020
- Status verified
- Mar 2023
- Primary completion
- Nov 30, 2023
- Completion
- Nov 1, 2023
Study Design
- Enrollment
- 94 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: A: Experimental GroupParticipants receive totally 3 cycles of camrelizumab combined with albumin-bound paclitaxel and Cisplatin/carboplatin/Nedaplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
- Active Comparator: B: Control groupParticipants receive totally 3 cycles of albumin-bound paclitaxel combined with Cisplatin/carboplatin/Nedaplatin treatment during preoperative period, every 3 weeks for up to 3 cycles.
Primary Outcome Measure
pathological complete response (pCR) [ Time Frame: The day of the surgery ]
Related Studies
- Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation TherapyRecruiting · The Cooper Health System · Camden, New Jersey